Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBIT (2016 - 2025)

Historic EBIT for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$40.0 million.

  • Viridian Therapeutics, Inc.\DE's EBIT rose 5206.88% to -$40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$328.1 million, marking a year-over-year decrease of 1592.56%. This contributed to the annual value of -$299.0 million for FY2024, which is 1752.21% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's EBIT stood at -$40.0 million, which was up 5206.88% from -$106.8 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's EBIT ranged from a high of -$14.1 million in Q3 2021 and a low of -$106.8 million during Q2 2025
  • Its 5-year average for EBIT is -$53.1 million, with a median of -$51.2 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Viridian Therapeutics, Inc.\DE's EBIT was 6790.11% (2021), while the steepest drop was 18236.59% (2021).
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's EBIT stood at -$29.1 million in 2021, then plummeted by 68.72% to -$49.1 million in 2022, then tumbled by 45.68% to -$71.5 million in 2023, then fell by 22.38% to -$87.5 million in 2024, then surged by 54.26% to -$40.0 million in 2025.
  • Its EBIT stands at -$40.0 million for Q3 2025, versus -$106.8 million for Q2 2025 and -$93.9 million for Q1 2025.